Stockreport

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug [Yahoo! Finance]

NeuroSense Therapeutics Ltd.  (NRSN) 
PDF PrimeC Has Previously Demonstrated Unprecedentedly Strong Clinical Efficacy; Wall Street Maintains Buy Rating with AGP giving the company a $7.50 Price Target Representi [Read more]